Trials
8 active
8 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up,…”In the company’s words, NCT05579132 on ClinicalTrials.gov
- Tested for
- Lymphoma, Large B-Cell, Diffuse (2 trials), Follicular Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies, Acute Lymphoblastic Leukemia and 5 more
- Main trialPhase 2/3
- “Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer…”In the company’s words, NCT07634471 on ClinicalTrials.gov
- Other names
- CN201
- Given with
- Avtozma (Celltrion Inc), Tyenne (Fresenius Kabi USA)Other companies’ drugs in its trials
Other drugs for Lymphoma, Large B-Cell, Diffuse
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- SHR-A1912Hengrui · Phase 3
- TisagenlecleucelNovartis · Phase 3
Coming up8
- 30 Sep 2028Phase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 16 Jul 2029Phase 1 trial completes · ClinicalTrials.gov
- 1 Jul 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 23 Jul 2032Phase 2/3 trial completes · ClinicalTrials.gov
- 18 Oct 2033Phase 2/3 trial completes · ClinicalTrials.gov
- 16 Nov 2033Phase 2 trial completes · ClinicalTrials.gov
- 13 Mar 2037Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 23 Jul 2032 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | |
| Phase 2/3Recruiting | 18 Oct 2033 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | |
| Phase 2/3Not yet recruiting | 13 Mar 2037 | A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | |
| Phase 2Recruiting | 16 Nov 2033 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | |
| Phase 1/2Recruiting | 31 Dec 2028 | A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) | |
| Phase 1/2Recruiting | 1 Jul 2030 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | |
| Phase 1Recruiting | 30 Sep 2028 | A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) | |
| Phase 1Recruiting | 16 Jul 2029 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026